Management

Jan Alan Alfheim

Chief Executive Officer

Tina Bjørnlund Bønsdorff

Chief Scientific Officer

Øyvind Sverre Bruland

Chief Medical Officer

Tore Kvam

Chief Financial Officer

Kristine Lofthus

Head of Quality Assurance

Kari Skinnemoen

Head of Regulatory Affairs

Helen Blanco

Head of Clinical Operations

Hans Hild

Head of Production

Gro Hjellum

Head of Quality Control

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.

Tina Bjørnlund Bønsdorff

Chief Scientific Officer

bonsdorff@oncoinvent.com

+47 470 24 922

Dr. Tina B. Bønsdorff has more than 15 years of research experience in molecular biology. She has a Ph.D. and postdoctoral experience from the Norwegian School of Veterinary Science, where she worked in the field of gene identification, expression and mutation analysis. Her postdoctoral research was focused on gene expression analysis of early neoplastic lesions in dog with inherited cancer syndromes. Dr. Bønsdorff is one of the founders of Oncoinvent AS. Dr. Bønsdorff has been the Chief Scientific Officer of Oncoinvent AS from the start-up, and was the CEO of the company from August 2013 to September 2016.

Øyvind Sverre Bruland

Chief Medical Officer

Dr. Øyvind S. Bruland is a MD, Ph.D. and professor of Clinical Oncology with the Faculty of Medicine, University of Oslo and senior consultant oncologist at the Dept. of Oncology, Oslo University Hospital and has supervised a large number of Ph.D. students in this capacity. He founded Algeta ASA in 1997 together with Dr. Roy H. Larsen, and he was one of the founders of Nordic Nanovector ASA (2009) and of Oncoinvent AS (2010). Øyvind S. Bruland served as a member of the board of Oncoinvent AS from 2010 to 2016. Professor Bruland’s main clinical experience and research has been devoted to primary bone and soft tissue cancers (sarcomas).

Tore Kvam

Chief Financial Officer

kvam@oncoinvent.com

+47 959 34 199

Tore Kvam has an extensive experience as CFO within technology driven companies and with a lifelong experience within financial management and operations, as well as working with investors and owners developing companies. In the later years he has also gained significant experience and knowledge within the life science industry working with clinical phase companies in their efforts to advance their product candidates and attract life science investors. Mr. Kvam holds a MSc Computer Science degree from the George Washington University, an MBA from the Norwegian Business School BI and is a Certified European Financial Analyst (CEFA).

Kristine Lofthus

Head of Quality Assurance

lofthus@oncoinvent.com

+47 932 06 611

Kristine Lofthus has more than 15 years experience with the manufacturing of pharmaceuticals. Her main field of expertise is the manufacturing of aseptic and terminally sterilized injectables, and in particular radiopharmaceuticals. This experience includes production and production management, quality assurance and the certification and release of batches as a Qualified Person. Kristine holds a cand. pharm. degree (M.Sc.) from the University of Oslo, a certificate of Advanced Studies (CAS) in Radiopharmaceutical Chemistry/Radiopharmacy from Eidgenössische Technische Hochschule Zürich and is a licensed Qualified Person at Oncoinvent AS

 

Kari Skinnemoen

Head of Regulatory Affairs

skinnemoen@oncoinvent.com

+47 906 99 816

Kari Skinnemoen has more than 35 years’ experience in the pharmaceutical and medical device industries within global regulatory affairs, quality assurance, quality control and research and development. This experience includes management and project management positions within the development of contrast media (Nycomed Imaging now GE Healthcare), photodynamic therapy of skin cancers (Photocure) and in-vitro diagnostic products (Alere Technologies).  She is licensed as Qualified Person for batch release at Oncoinvent. Kari holds a cand. real. degree (M.Sc.) from University in Oslo in chemistry, mathematics and biology with a thesis in organic chemistry.

 

Helen Blanco

Head of Clinical Operations

blanco@oncoinvent.com

+47 476 32 029

Helén Johansen Blanco has 20 years of clinical development experience, ranging from Phase I to III clinical trials leading to the successful launch of several oncology products. She has experience in project management of large global clinical trials conducted in all continents of the world. Mrs. Blanco has previously worked for large international pharma companies such as Astra Zeneca, Mylan Biologics and Celgene, as well as medium sized biotechnology companies and recognized clinical research organizations such as Covance. She holds a MSc in Biophysics and medical technology from NTNU.

 

Hans Hild

Head of Production

hild@oncoinvent.com

+47 971 24 060

Dr. Hans M. Hild has more than 15 years’ experience in the GMP compliant production of sterile- and aseptically produced pharmaceuticals and radiopharmaceuticals. He previously has worked for the Institute for Energy Technology, GE Healthcare, Avecia Biotechnology (formerly Zeneca LSM Ltd.) and Degussa AG, and has a strong background in pharmaceutical process development, scale-up and technology transfer. He has extensive experience in the production of biopharmaceuticals and contrast media for early clinical studies, as well as experience in the commercial production of radiopharmaceuticals. Dr. Hild holds an Dipl. Ing. (FH) degree in Chemical Engineering from FH Frankfurt am Main, an M.Sc. in Biochemical Engineering from the University of Birmingham and a Ph.D. in Biochemical Engineering from Imperial College London.

Gro Hjellum

Head of Quality Control

hjellum@oncoinvent.com

+47 979 83 092

Gro Hjellum has more than 25 years of experience within research & development and operations in the pharmaceutical and biotech industry, ranging from analytical sciences, quality control and bio-analysis from preclinical product development through to regulatory approval of products. Prior to joining Oncoinvent, Gro worked for Nycomed/GE-Healthcare and Algeta/Bayer. She has a strong background in radiopharmaceutical product development and technology transfer to contract manufacturers in Norway as well as to US and Japan. Ms. Hjellum holds an MSc degree in radiochemistry from the University of Oslo.